EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Assessment of the Lifetime Costs of Severe Visual Impairment Due to Retinitis Pigmentosa

Dejan Milentijevic, Christine Ferro, Sara Rosenblum, Gabriela Dieguez

ClinicoEconomics and Outcomes Research · 2026-04 · Volume 18 · 1-15

DOI: 10.2147/ceor.s571305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2026-04. Verfasst von Dejan Milentijevic und 3 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson Innovative Medicine, Titusville, NJ, USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

blindnessdisabilitygene therapyinherited retinal diseasesretinitis pigmentosa

Autor:innen und Institutionen

  • Johnson & Johnson Innovative Medicine, Titusville, NJ, USA.
  • Milliman, Inc., New York, NY, USA.

Zitieren

APA

Milentijevic, D., Ferro, C., Rosenblum, S., & Dieguez, G. (2026). Assessment of the Lifetime Costs of Severe Visual Impairment Due to Retinitis Pigmentosa. ClinicoEconomics and Outcomes Research, Volume 18, 1-15. https://doi.org/10.2147/ceor.s571305

Vancouver

Milentijevic D, Ferro C, Rosenblum S, Dieguez G. Assessment of the Lifetime Costs of Severe Visual Impairment Due to Retinitis Pigmentosa. ClinicoEconomics and Outcomes Research. 2026;Volume 18:1-15. doi:10.2147/ceor.s571305

BibTeX
@article{Milentijevic2026,
  author = {Milentijevic, Dejan and Ferro, Christine and Rosenblum, Sara and Dieguez, Gabriela},
  title = {Assessment of the Lifetime Costs of Severe Visual Impairment Due to Retinitis Pigmentosa},
  journal = {ClinicoEconomics and Outcomes Research},
  year = {2026},
  volume = {Volume 18},
  pages = {1--15},
  doi = {10.2147/ceor.s571305}
}
Kostenlos starten →